Allen Rassa, MD
Interventional Cardiology · Bremerton, WANPI 1932465424
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Shockwave Medical, Inc at 57.9% of the total. Reporting peaked in 2023 at $10,164 and has fallen 85.4% since, to $1,480 in 2025.
Across 127 payments — averaging $116.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$9K
- Medtronic$2K
- Boston Scientific$979
- E.r. Squibb & Sons, L.L.C.$570
- Boehringer Ingelheim$450
- Penumbra, Inc.$262
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$6,60044%
- Travel & lodging$3,57724%
- Food & beverage$4,60331%
- Education$771%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 13 | $8,609 |
| Medtronic(2 entities) | 14 | $2,165 |
| Boston Scientific | 5 | $979 |
| E.r. Squibb & Sons, L.L.C. | 14 | $570 |
| Boehringer Ingelheim | 5 | $450 |
| Penumbra, Inc. | 12 | $262 |
| Kaneka Medical America LLC | 1 | $246 |
| Inari Medical, Inc. | 9 | $242 |
| Abbott | 5 | $238 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $223 |
| Novartis | 9 | $193 |
| Abiomed | 3 | $186 |
| Bridgebio Pharma, Inc. | 1 | $123 |
| Kestra Medical Technology Services, Inc. | 3 | $95 |
| Cardiovascular Systems Inc. | 8 | $80 |
| Teleflex LLC | 2 | $55 |
| Heartflow, Inc. | 2 | $55 |
| Circa Scientific, Inc. | 1 | $24 |
| Pfizer | 1 | $18 |
| Merck | 1 | $16 |
| Biotronik Inc. | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$8,398
- Resolute$1,250
- WATCHMAN Access System$962
- JARDIANCE$367
- Apheresis Machine$246
- COROFLOW$183
- SYMPLICITY G3$160
- Impella$145
- Avalus$130
- RESOLUTE ONYX$129
- Attruby$123
- FLOWTRIEVER CATHETER, S$116
- CT THROMBECTOMY SYSTEM KIT$116
How this compares
$14,858 in reported general payments places this provider in the 75th percentile of 125 interventional cardiology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 17 | $376,009 |
| EliquisApixaban | 188 | $240,377 |
| XareltoRivaroxaban | 93 | $109,679 |
| JardianceEmpagliflozin | 57 | $87,345 |
| EntrestoSacubitril/Valsartan | 55 | $75,880 |
| Repatha SureclickEvolocumab | 43 | $41,616 |
| BrilintaTicagrelor | 12 | $9,554 |
| Praluent PenAlirocumab | 11 | $9,033 |
| Metoprolol Succinate | 380 | $5,290 |
| Ranolazine ErRanolazine | 11 | $3,343 |
| Atorvastatin Calcium | 325 | $3,310 |
| Ezetimibe | 74 | $2,632 |
| ClopidogrelClopidogrel Bisulfate | 173 | $2,069 |
| Spironolactone | 195 | $1,797 |
| Torsemide | 102 | $1,770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $18 | $616,386205 claims |
| Boehringer IngelheimJardiance | $450 | $87,34557 claims |
| NovartisEntresto | $193 | $75,88055 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 125 interventional cardiology providers in Washington.
Other interventional cardiology in Bremerton
- Abdulfattah SaidiBremerton$8K
- Satyavardhan PulukurthyBremerton$6K
- William LombardiSeattle$902K
- Kathleen KearneySeattle$448K
- Robert RileyBellevue$431K
- Danny DvirSeattle$374K
- James McCabeSeattle$289K
- Christopher BrownSeattle$266K
- Lorenzo AzzaliniSeattle$233K
- Sidakpal PanaichSeattle$214K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.